BSE - Delayed Quote INR

Zydus Lifesciences Limited (ZYDUSLIFE.BO)

Compare
988.20 -17.00 (-1.69%)
At close: 3:29 PM GMT+5:30
Currency in INR All numbers in thousands
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
3/31/2020
Total Revenue
200,152,000.00
190,215,000.00
168,778,000.00
148,276,000.00
141,250,000.00
--
Cost of Revenue
64,121,000.00
65,004,000.00
65,589,000.00
58,189,000.00
50,708,000.00
--
Gross Profit
136,031,000.00
125,211,000.00
103,189,000.00
90,087,000.00
90,542,000.00
--
Operating Expense
85,223,000.00
79,816,000.00
74,640,000.00
65,320,000.00
63,168,000.00
--
Operating Income
50,808,000.00
45,395,000.00
28,549,000.00
24,767,000.00
27,374,000.00
--
Net Non Operating Interest Income Expense
635,000.00
776,000.00
-541,000.00
-511,000.00
-1,146,000.00
--
Pretax Income
53,794,000.00
48,089,000.00
25,897,000.00
28,381,000.00
23,992,000.00
--
Tax Provision
11,975,000.00
9,775,000.00
5,878,000.00
5,117,000.00
1,936,000.00
--
Net Income Common Stockholders
41,925,000.00
38,595,000.00
19,603,000.00
44,873,000.00
21,336,000.00
--
Diluted NI Available to Com Stockholders
41,925,000.00
38,595,000.00
19,603,000.00
44,873,000.00
21,336,000.00
--
Basic EPS
41.51
38.14
19.30
43.83
20.84
--
Diluted EPS
41.51
38.14
19.30
43.83
20.84
--
Basic Average Shares
1,010,500.94
1,011,926.84
1,015,649.87
1,023,742.60
1,023,742.60
--
Diluted Average Shares
1,010,500.94
1,011,926.84
1,015,649.87
1,023,742.60
1,023,742.60
--
Rent Expense Supplemental
--
261,000.00
229,000.00
206,000.00
215,000.00
--
Total Expenses
149,344,000.00
144,820,000.00
140,229,000.00
123,509,000.00
113,876,000.00
--
Net Income from Continuing & Discontinued Operation
41,925,000.00
38,595,000.00
19,603,000.00
44,873,000.00
21,336,000.00
--
Normalized Income
40,752,130.16
37,522,058.54
29,455,892.54
20,281,492.55
24,011,814.27
--
Interest Income
--
1,268,000.00
757,000.00
688,000.00
495,000.00
--
Interest Expense
581,000.00
440,000.00
1,255,000.00
1,144,000.00
1,559,000.00
--
Net Interest Income
635,000.00
776,000.00
-541,000.00
-511,000.00
-1,146,000.00
--
EBIT
54,375,000.00
48,529,000.00
27,152,000.00
29,525,000.00
25,551,000.00
--
EBITDA
62,371,000.00
56,170,000.00
34,379,000.00
36,886,000.00
32,799,000.00
--
Reconciled Cost of Revenue
64,121,000.00
65,004,000.00
65,589,000.00
58,189,000.00
50,708,000.00
--
Reconciled Depreciation
7,996,000.00
7,641,000.00
7,227,000.00
7,361,000.00
7,248,000.00
--
Net Income from Continuing Operation Net Minority Interest
41,685,000.00
38,365,000.00
19,649,000.00
22,416,000.00
22,016,000.00
--
Total Unusual Items Excluding Goodwill
1,200,000.00
1,058,000.00
-5,001,000.00
2,604,000.00
-2,171,000.00
--
Total Unusual Items
1,200,000.00
1,058,000.00
940,000.00
2,604,000.00
-2,171,000.00
--
Normalized EBITDA
61,171,000.00
55,112,000.00
33,439,000.00
34,282,000.00
34,970,000.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
267,130.16
215,058.54
-1,135,107.46
469,492.55
-175,185.73
--
3/31/2020 - 7/18/2001

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers